Drug Type Radiopharmaceuticals and diagnostic agent, Radionuclide Drug Conjugates (RDC) |
Synonyms 177Lu-PSMA-3D1015, 3D 1015, 3D1015 |
Target |
Action inhibitors |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| PSMA-Positive Castration-Resistant Prostatic Cancer | Clinical | China | 28 Aug 2025 | |
| Metastatic castration-resistant prostate cancer | Preclinical | China | 02 Apr 2025 |





